The stock has a 36-month beta value of 1.19. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TNXP is 6.43M, and at present, short sellers hold a 13.66% of that float. On March 31, 2025, the average trading volume of TNXP was 1.66M shares.
TNXP) stock’s latest price update
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has experienced a decline in its stock price by -24.37 compared to its previous closing price of 26.67. However, the company has seen a fall of -12.42% in its stock price over the last five trading days. globenewswire.com reported 2025-03-27 that CHATHAM, N.J., March 27, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D.
TNXP’s Market Performance
TNXP’s stock has fallen by -12.42% in the past week, with a monthly rise of 146.58% and a quarterly drop of -47.65%. The volatility ratio for the week is 25.29% while the volatility levels for the last 30 days are 22.82% for Tonix Pharmaceuticals Holding Corp The simple moving average for the past 20 days is 14.17% for TNXP’s stock, with a -39.30% simple moving average for the past 200 days.
Analysts’ Opinion of TNXP
ROTH Capital, on the other hand, stated in their research note that they expect to see TNXP reach a price target of $4. The rating they have provided for TNXP stocks is “Buy” according to the report published on April 18th, 2019.
ROTH Capital gave a rating of “Buy” to TNXP, setting the target price at $6 in the report published on August 18th of the previous year.
TNXP Trading at 6.06% from the 50-Day Moving Average
After a stumble in the market that brought TNXP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.17% of loss for the given period.
Volatility was left at 22.82%, however, over the last 30 days, the volatility rate increased by 25.29%, as shares surge +156.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.17% lower at present.
During the last 5 trading sessions, TNXP fell by -12.42%, which changed the moving average for the period of 200-days by -90.87% in comparison to the 20-day moving average, which settled at $17.67. In addition, Tonix Pharmaceuticals Holding Corp saw -38.84% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for TNXP
Current profitability levels for the company are sitting at:
- -7.7 for the present operating margin
- 0.23 for the gross margin
The net margin for Tonix Pharmaceuticals Holding Corp stands at -12.88. The total capital return value is set at -0.54. Equity return is now at value -106.12, with -81.95 for asset returns.
Based on Tonix Pharmaceuticals Holding Corp (TNXP), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -11.41.
Currently, EBITDA for the company is -71.73 million with net debt to EBITDA at 1.26. When we switch over and look at the enterprise to sales, we see a ratio of 3.6. The receivables turnover for the company is 1.25for trailing twelve months and the total asset turnover is 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.50.
Conclusion
To sum up, Tonix Pharmaceuticals Holding Corp (TNXP) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
